Page 49 - TD-1-1

Tumor Discovery A bioinformatics analysis of PD-1 in cancers

carcinoma. Clin Cancer Res, 13(6): 1757–1761. https://doi.org/10.3233/cbm-170357
https://doi.org/10.1158/1078-0432.ccr-06-2599 27. Du XL, Zhang DM, Xu H, et al., 2021, Relationship
between the expression of PD-1, PD-L1 and Cyclin D1
14. Yang S, Zhang YH, Sun YL, et al., 2016, Expressions of
programmed death 1, programmed death ligand-1 and nerve protein and prognosis in ovarian cancer. J Mol Diagn Ther,
growth factor in liver cancer tissues and their significance. 13(10): 1680–1684.
Infect Dis Inf, 29(2): 92–96. 28. Zhu WW, 2017, Expression of PD-1 and PD-L1 in gastric
15. Liu TM, Song Z, Wang WH, et al, 2019, Expression of GPC1 and cancer tissues and its clinical significance. Henan Med Res,
PD-1 in non-small cell lung cancer tissues and their correlation 26(18): 3302–3304.
with patient prognosis. Chin J Gerontol, 39(8): 66–68. 29. Wu S, Shao JY, Wang F, et al., 2015, Expression and clinical
16. Shao JY, 2015, Research update on PD-1 and its ligand significance of PD-L1 and PD-1 in gastric carcinoma. Acta
PD-L1 in malignant tumor. J Int Oncol, 42(5): 358–360. Univ Med, 6: 103–107.
17. Abhisek SW, Hammond WA and Joseph RW, 2015, Current 30. Li YF, Bao F, Xiang Y, et al., 2018, Expression of PD1/
state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. PD-L1 in gastric carcinoma and its correlation with
Mol Immunol, 67(2 Pt A): 4–17. clinicopathological characteristics and prognosis. Chin J
Clin Exp Pathol, 34: 614–618.
https://doi.org/10.1016/j.molimm.2015.02.009
31. Deng Y, Ma YT, 2021, The expression of PD-1/PD-L1 in gastric
18. Zhong YC, Lu X, Yang Y, et al., 2019, The expression and cancer and its clinical significance. Mod Med J, 34(14): 4.
value of PD-1, PDL-1 and T lymphocyte subsets in breast
cancer. Chongqing Yixue, 2019(18): 3134–3137. 32. Feng TB, 2019, The expression and pathological significance
of PD-L1 and PD-1 in gastric cancer. Mod Diagn Treatment,
19. Justin L, Tze-Chen H, Dorota HH, et al., 2018, Upregulation 30(6): 849–851.
of PD-L1 expression by resveratrol and piceatannol in
breast and colorectal cancer cells occurs via HDAC3/p300- 33. Takaya S, Saito H and Ikeguchi M. Upregulation of immune
mediated NF-κB signaling. Int J Oncol, 53(4): 1469–1480. checkpoint molecules, PD-1 and LAG-3, on CD4+ and
CD8+ T cells after gastric cancer surgery. Yonago Acta
https://doi.org/10.3892/ijo.2018.4512 Medica, 58(1): 39–44.
20. Jia XP, Meng LL, Li HL, et al., 2021, Differential expression 34. Qu HW, Jin JP, Chang T, 2019, Expression and clinical
and clinical significance of PD-1, PD-L1 and FOXP3 in significance of PDCD1 in nasopharyngeal carcinoma
triple-negative breast cancer and non-triple-negative breast tissues. Chin Clin Oncol, 24(4): 21–26.
cancer tissues. J Med Inf, 34: 7–11.
35. Shi HJ, Li JR, Yan QJ, et al., 2019, Expression and clinical
https://doi.org/10.1016/j.clbc.2018.05.006 significance of PD-1,PD- L1 and TIM-3 in oral squamous
21. Yu XQ, Zhang SW, Chen F, et al., 2019, Detection and cell carcinoma. Henan Med Res, 28(11): 1924–1926.
significance of Tim-3 and PD-1 expression levels on the 36. Ansell SM, Lesokhin AM, Borrello I, et al., 2015, PD-1
surface of PBMCs in peripheral blood of patients with HBV- blockade with nivolumab in relapseed or refractory
related liver diseases. China J Mod Med, 69(7): 43–47. Hodgkin’s lynphoma. N Engl J Med, 372(4): 311–319.
22. Nebbia G, Peppa D, Schurich A, et al., 2012, Upregulation of 37. Mezache L, Paniccia B, Nyinawabera A, et al., 2015,
the tim-3/galectin-9 pathway of T cell exhaustion in chronic Enhanced expression of PD L1 in cervical intraepithelial
hepatitis B virus infection. PLoS One, 7(10): e47648.
neoplasia and cervical cancers. Mod Pathol, 28(12):
https://doi.org/10.1371/journal.pone.0047648 1594–602.
23. Zhou QS, Wei Z, Du JH, 2019, Changes and clinical significance https://doi.org/10.1038/modpathol.2015.108
of expression of PD-1,PD-L1 and CEA 125 in primary 38. Powles T, Eder JP, Fine GD, et al., 2014, MPDL3280A (anti-
hepatocellular carcinoma. Mod Digest Intervent, 24(8): 851–854.
PD-L1) treatment leads to clinical activity in metastatic
24. Li PY, Ke XL, Zhu Q, et al., 2013, Expression and clinical bladder cancer. Nature, 515(7528): 558–562.
significance of nerve growth factor in primary liver cancer. https://doi.org/10.1038/nature13904
Chin J Hepatol, 21(2): 121–124.
39. Starke A, Lindenmeyer MT, Segerer S, et al., 2010, Renal
25. Hu JW, Zhang XJ, Cai GY, et al., 2021, The expression and
clinical significance of PD-1 and IFN-γ in peripheral blood of tubular PD-L1 (CD274) suppresses alloreactive human
patients with primary hepatic carcinoma. Mod Med J, 49(7): 4. T-cell responses. Kidney Int, 78(1): 38–47.
https://doi.org/10.1038/ki.2010.97
26. Tan D, Sheng L, Yi QH, 2018, Correlation of PD-1/PD-L1
polymorphisms and expressions with clinicopathologic 40. Wolchok JD, Kluger H, Callahan MK, et al., 2013, Nivolumab
features and prognosis of ovarian cancer. Cancer Biomark, plus ipilimumab in advanced melanoma. N Engl J Med,
21(2): 287–297. 369(2): 122–133.

Volume 1 Issue 1 (2022) 10 https://doi.org/10.36922/td.v1i1.59